Phase II study of amonafide in advanced pancreatic adenocarcinoma.

Journal Article (Clinical Trial;Journal Article)

To determine the efficacy of amonafide in patients with advanced, measurable pancreatic adenocarcinoma, 15 patients previously untreated with chemotherapy were entered on a phase II trial. The starting dose was 400 mg/m2 administered daily over 1 hr for 5 consecutive days repeated every 3 weeks. Because of grade 4 myelosuppression observed in the initial 2 patients, the daily starting dose was decreased to 350 mg/m2. Of the 15 patients, 14 were evaluable. Amonafide failed to produce clinical responses in the doses and schedule employed. Grade 4 granulocytopenia was observed in 3 of 9 courses at 400 mg/m2, 3 of 12 courses at 350 mg/m2 and in 1 of 4 courses at 300 mg/m2. Grade 4 thrombocytopenia was observed in 3 courses at 400 mg/m2. Nonhematologic toxicities included mild nausea and vomiting and skin rashes.

Full Text

Duke Authors

Cited Authors

  • Linke, K; Pazdur, R; Abbruzzese, JL; Ajani, JA; Winn, R; Bradof, JE; Daugherty, K; Levin, B

Published Date

  • November 1991

Published In

Volume / Issue

  • 9 / 4

Start / End Page

  • 353 - 356

PubMed ID

  • 1804812

International Standard Serial Number (ISSN)

  • 0167-6997

Digital Object Identifier (DOI)

  • 10.1007/BF00183580


  • eng

Conference Location

  • United States